Understanding of Genetics by Men at Risk for Prostate Cancer
Recruiting · NCT04550845 · Interventional (participants receive a specific treatment) · Lead sponsor: Mayo Clinic
View the official record on ClinicalTrials.gov →Interventions studied
Focus group analyses
What this trial is about
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understanding of prognostic genetic technology in African American and rural White men at risk for localized prostate cancer.
Who can take part
Age range
40 Years to 95 Years
Sex
Male
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- African-American or White men
- Living in a rural or urban areas
- Age 40 to 95 years old
- Able and willing to provide informed consent
- English-speaking
- Willing to participate in the study.
- This study will use the United States Department of Agriculture Office of Rural Development's definition of rural, which is as a city or town that has a population less than 50,000 inhabitants to define rural.
- This study will use the United States Census Bureau's definition of urban, which is a city or town that has a population greater than 50,000 inhabitants to define urban.
Exclusion criteria
- Women will be excluded from participating in this study. However, women will be recruited to serve on an advisory panel to review the video-based educational tool for the comprehension of genomic terminology for prognostic genetic testing in patients with localized prostate cancer.
Where it is running
3 locations listed across 3 US states.
- Mayo Clinic - Phoenix, Arizona, United States
- Mayo Clinic in Florida - Jacksonville, Florida, United States
- Mayo Clinic - Rochester, Minnesota, United States